SCHEMBL2319306

SCHEMBL2319306

CC1(C)CC(O)CC(C)(CNc2ccccc2Cl)C1

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 1/20 0.43
P2RX7 Q99572 3/20 0.39
L3MBTL1 Q9Y468 3/20 0.36
RAB9A P51151 2/20 0.36
ALDH1A1 P00352 3/20 0.36
GAA P10253 2/20 0.36
KDM4E B2RXH2 1/20 0.36
EBP Q15125 1/20 0.34
SIGMAR1 Q99720 1/20 0.34
KMT2A Q03164 2/20 0.33
SMN1; SMN2 Q16637 3/20 0.33
LMNA P02545 2/20 0.33
ADRA2B P18089 1/20 0.33
ADRA2C P18825 1/20 0.33
MAPT P10636 1/20 0.33
IDO1 P14902 1/20 0.33
NPC1 O15118 1/20 0.32
MEN1 O00255 1/20 0.32
NPSR1 Q6W5P4 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12350739 0.90 HSD11B1 (0.39) HSD11B1P2RX7ALDH1A1KDM4EKMT2A
SCHEMBL2322132 0.81 HSD11B1 (0.41) HSD11B1L3MBTL1ALDH1A1GAASIGMAR1
SCHEMBL12350687 0.80 HSD11B1 (0.46) HSD11B1P2RX7L3MBTL1ALDH1A1KDM4E
SCHEMBL2322122 0.78 HSD11B1 (0.39) HSD11B1P2RX7RAB9AKMT2ALMNA
SCHEMBL2321362 0.77 HSD11B1 (0.40) HSD11B1RAB9AALDH1A1GAAKMT2A
SCHEMBL2324011 0.76 HSD11B1 (0.43) HSD11B1KMT2ALMNAMEN1
SCHEMBL12350721 0.75 HSD11B1 (0.42) HSD11B1P2RX7
SCHEMBL2360451 0.75 KDM4E (0.43) HSD11B1P2RX7L3MBTL1RAB9AALDH1A1
SCHEMBL2322874 0.74 HSD11B1 (0.41) HSD11B1L3MBTL1RAB9AALDH1A1GAA
SCHEMBL2327372 0.72 HSD11B1 (0.40) HSD11B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2011094953-A1 COMPOUNDS FOR THE TREATMENT AND PREVENTION OF INFLUENZA F. HOFFMANN-LA ROCHE AG (CH) 2011-08-11 WO disclosed
WO-2011095576-A1 COMPOUNDS FOR THE TREATMENT AND PREVENTION OF INFLUENZA F. HOFFMANN-LA ROCHE AG (CH) 2011-08-11 WO disclosed
WO-2011094953-A1 COMPOUNDS FOR THE TREATMENT AND PREVENTION OF INFLUENZA F. HOFFMANN-LA ROCHE AG (CH) 2011-08-11 WO disclosed
WO-2011095576-A1 COMPOUNDS FOR THE TREATMENT AND PREVENTION OF INFLUENZA F. HOFFMANN-LA ROCHE AG (CH) 2011-08-11 WO disclosed
US-20110195979-A1 COMPOUNDS FOR THE TREATMENT AND PREVENTION OF INFLUENZA F. HOFFMANN-LA ROCHE AG (CH) 2011-08-11 US disclosed
US-20110195979-A1 COMPOUNDS FOR THE TREATMENT AND PREVENTION OF INFLUENZA F. HOFFMANN-LA ROCHE AG (CH) 2011-08-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110195979-A1 COMPOUNDS FOR THE TREATMENT AND PREVENTION OF INFLUENZA NAT1, NHERF1, ADORA1 HSD11B1 433/4885P2RX7 830/4885L3MBTL1 3035/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.